A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject
Status:
Completed
Trial end date:
2018-03-19
Target enrollment:
Participant gender:
Summary
HL237 is a new autoimmune therapeutic agent for rheumatoid arthritis, including the basic
structure of biguanide in metformin, an existing diabetes drug.
The immune modulating activity of HL237 was demonstrated in animal model. HL237 is a STAT3
inhibitor and STAT3 is well known for an important regulator inhibiting Th17 cells and
activating Treg cells.
Therefore, when STAT3 activity is inhibited, it is expected to be able to treat autoimmune
diseases such as rheumatoid arthritis.
This is the first clinical trial to be conducted for the development of HL237 and this
clinical trial is for determining the maximum oral dose of HL237 and assessing safety,
tolerability, and pharmacokinetic characteristics for each dose group.